Patent US4634590A successfully refreshed from Google Patents.
US4634590A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Cell membrane proteins, compositions containing them and procedure for their preparation
Assignee: Yeda Research and Development Co Ltd
•
Filing: 1984-09-07
•
Granted: 1987-01-06
•
Expires: 2004-09-07
Abstract
Abstract Compositions for the prevention of, and for the treatment of autoimmune diseases which comprise as active ingredient membrane material shed from autoimmune T lymphocytes, or T lymphocytes activated by a pressure application and release process. There is also provided a process for obtaining such active materials and for preparing pharmaceutical compositions for these.
Inventors
- 👤 Irun R. Cohen
- 👤 Meir Shinitzky
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 07:24
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/705; A; A61; A61K; A61K38/00; Y; Y10; Y10S; Y10S424/00; Y10S424/81; Y10S435/00; Y10S435/82; Y10S435/8215; Y10S435/948; Y10S530/00; Y10S530/806
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
98 words
A method for recovering purified membrane proteins from T lymphocyte cells useful for preventing or treating a specific autoimmune disease which comprises: (a) suspending T lymphocyte cells specific for the autoimmune disease in a buffer; (b) subjecting the suspended cells to hydrostatic pressure and then releasing the pressure on the suspended cells so as to cause the cells to shed membrane proteins which retain biological activity; (c) centrifuging the depressurized suspension to remove cell fragments and produce a supernatant containing the membrane proteins; and (d) treating the supernatant by ultracentrifugation so as to recover the purified membrane proteins.
Claim 2
Independent Claim
98 words
A method for recovering purified membrane proteins from T lymphocyte cells useful for preventing or treating a specific autoimmune disease which comprises: (a) suspending T lymphocyte cells specific for the autoimmune disease in a buffer; (b) subjecting the suspended cells to hydrostatic pressure and then releasing the pressure on the suspended cells so as to cause the cells to shed membrane proteins which retain biological activity; (c) centrifuging the depressurized suspension to remove cell fragments and produce a supernatant containing the membrane proteins; and (d) treating the supernatant by ultracentrifugation so as to recover the purified membrane proteins.
Claim 3
Dependent Claim
18 words
A method of claim 1, wherein the suitable hydrostatic pressure is from about 500 to about 1500 atmospheres.
Claim 4
Dependent Claim
21 words
Purified membrane proteins derived from T lymphocyte cells specific for a specific autoimmune disease produced by the method of claim 1.
Claim 5
Dependent Claim
28 words
A composition for preventing or treating a specific autoimmune disease which comprises purified membrane proteins of claim 3 specific for the autoimmune disease, and a pharmaceutically acceptable carrier.
Claim 6
Dependent Claim
39 words
A method for preventing or treating a specific autoimmune disease in a subject which comprises administering to the subject by an appropriate route an effective amount of a composition of claim 4 to prevent or treat the autoimmune disease.
Claim 7
Dependent Claim
22 words
Purified membrane proteins of claim 3, wherein the autoimmune disease is multiple sclerosis, thyroiditis, diabetes (Type I), ankylosing spondylitis or rheumatoid arthritis.
Claim 8
Independent Claim
36 words
A method for preventing or treating in a subject multiple sclerosis, thyroiditis, diabetes (Type I), ankylosing spondylitis, or rheumatoid arthritis which comprises administering to the subject an effective amount of a membrane protein of caim 6.
Claim 9
Independent Claim
36 words
A method for preventing or treating in a subject multiple sclerosis, thyroiditis, diabetes (Type I), ankylosing spondylitis, or rheumatoid arthritis which comprises administering to the subject an effective amount of a membrane protein of caim 6.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-01-05 | 1990-07-07 | 1991-01-06 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-01-05 | 1994-07-07 | 1995-01-06 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-01-05 | 1998-07-07 | 1999-01-06 | $7700.00 | Window Closed / Lapsed |